

Jurjen Versluis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8316713/publications.pdf>

Version: 2024-02-01

34
papers

1,312
citations

687363

13
h-index

552781

26
g-index

35
all docs

35
docs citations

35
times ranked

2262
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 509-517.	10.7	390
2	Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40â€“60 years. <i>Leukemia</i> , 2015, 29, 1041-1050.	7.2	123
3	Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 1079-1086.	1.4	119
4	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
5	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
6	Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. <i>Lancet Haematology</i> , the, 2015, 2, e427-e436.	4.6	88
7	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017, 1, 477-485.	5.2	76
8	Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. <i>Leukemia</i> , 2015, 29, 51-57.	7.2	67
9	Comparative value of post-remission treatment in cytogenetically normal AML subclassified by <i>NPM1</i> and <i>FLT3-ITD</i> allelic ratio. <i>Leukemia</i> , 2017, 31, 26-33.	7.2	59
10	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	2.4	36
11	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	2.4	32
12	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , the, 2021, 8, e205-e215.	4.6	26
13	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. <i>Journal of Internal Medicine</i> , 2018, 283, 371-379.	6.0	19
14	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	3.0	14
15	Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, e246-e249.	3.5	13
16	Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. <i>Seminars in Hematology</i> , 2019, 56, 164-170.	3.4	12
17	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolimmunology</i> , 2016, 5, e1105431.	4.6	11
18	Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 373-385.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. <i>Blood Advances</i> , 2022, 6, 2835-2846.	5.2	8
20	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020, 55, 2244-2253.	2.4	6
21	Acute Myeloid Leukemia in Adults. , 2019, , 507-521.		4
22	The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. <i>Cancer Medicine</i> , 2022, 11, 630-640.	2.8	3
23	Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 4041-4041.	1.4	2
24	Pretreatment clinical and genetic factors predict early post-treatment mortality in fit <sc>AML</sc> patients following induction. <i>American Journal of Hematology</i> , 2021, 96, E259-E262.	4.1	1
25	Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission. <i>Blood</i> , 2014, 124, 321-321.	1.4	1
26	Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems. <i>Blood</i> , 2012, 120, 734-734.	1.4	1
27	The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis. <i>Blood</i> , 2014, 124, 1209-1209.	1.4	1
28	Hepatitis E Virus: A Novel Opportunistic Pathogen in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4137-4137.	1.4	0
29	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. <i>Blood</i> , 2014, 124, 681-681.	1.4	0
30	The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio. <i>Blood</i> , 2014, 124, 323-323.	1.4	0
31	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3467-3467.	1.4	0
32	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 43-43.	1.4	0
33	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. <i>Blood</i> , 2021, 138, 608-608.	1.4	0
34	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. <i>Blood</i> , 2021, 138, 3438-3438.	1.4	0